Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Mevalotin Useful Against CAD in Elderly Women
April 7, 2008
- Surveys Show Increasing Interest in Generics
April 7, 2008
- Self-Injection at Home a Boon to Patients with Migraines
April 7, 2008
- Aiming at Eliminating "Drug Lag": New PMDA Chief Executive
April 7, 2008
- Long QT Risk Can Be Assessed Using Proarrhythmia Model
April 7, 2008
- Chuikyo Approves NHI Prices for 21 Products (14 APIs)
April 7, 2008
- Toyama Chemical to Review Licensing Policy
April 7, 2008
- TOPICS／Pfizer Starts Publicity Campaign on Growth Disorders in Girls
April 7, 2008
- 11 New Drugs to Be Officially Approved in April
April 7, 2008
- REGULATORY NEWS IN BRIEF
April 7, 2008
- Collaborative Multinational Clinical Trials Increasingly Diversified
April 7, 2008
- Japanese Patients Account for Nearly 50% of Total in Asian Studies
April 7, 2008
- PMDA Set No Minimum Number of Japanese Patients Required in Multinational Trials: Mr Mori
April 7, 2008
- Isao Teshirogi Appointed Shionogi President
April 7, 2008
- PMDA to Enhance Cooperation with Authorities in Other East Asian Countries: Mr Mori
April 7, 2008
- SELF-MEDICATION NEWS IN BRIEF
April 7, 2008
- Notices Received for 35 Collaborative Multinational Trials: Mr Mori
April 7, 2008
- Serious Effort Needed to Bring about Improvements : FJPWA President Matsutani
April 7, 2008
- Takeda Discontinues Development of TAK-475
April 7, 2008
- BUSINESS NEWS IN BRIEF
April 7, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…